![]() |
|
|
Vol. 26, Issue 1, 78-82, January 1998
Department of Pharmacology, College of Pharmacy, The
University of Toledo
The cytochrome P450 (CYP) subfamily responsible for ethosuximide
metabolism was investigated by HPLC assay of ethosuximide incubations
with isolated rat liver microsomes from control rats and from rats
treated with inducing agents to enrich hepatic microsomes in selected
CYP isoforms. Inducing agents included
-naphthoflavone (BNF, CYP1A
inducer), phenobarbital (PB, CYP2B/2C/3A), isoniazid (INH, CYP2E1),
clotrimazole (CTZ, CYP3A), clofibrate (CLO, CYP4A), and an imidazole
CTZ-analog known as CDD3543 (CYP3A). Incubations with BNF, INH, CTZ,
and control microsomes showed significantly (p<0.05) more
metabolite produced by CTZ microsomes vs. BNF, INH, and
control microsomes at 10, 30, 60, and 120 min incubation. Ethosuximide
metabolite levels generated by CTZ microsomes at 120 min were 36.5 times those of control microsomes. Correspondingly, ethosuximide
concentrations were significantly (p<0.05) lower for
incubations with the CTZ microsomes compared with BNF, INH, and control
microsomes at 60 and 120 min. Sixty-minute incubations with all
microsome groups exhibited significantly (p<0.05) higher metabolite
formation rates (nmol/nmol CYP/min) for CTZ (11.8x control) and PB
(9.6x control) microsomes vs. all other groups. Antibody
inhibition experiments demonstrated ethosuximide metabolite levels for
PB microsomes were not affected by CYP2B1 antibodies, whereas CYP3A2
antibodies reduced metabolite levels for both PB and CTZ microsomes by
over 80%. These results indicate CYP3A is primarily responsible for
ethosuximide metabolism in rats.